Breast Cancer Treatment Market- Business Growth, Regional Trends, Sales Revenue, Size, Development Status, Key Players Analysis And Comprehensive Research Study Till 2022

“Credence Research”
The latest market report published by Credence Research, Inc. “Global Breast Cancer Treatment Market- Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 – 2022,” the breast cancer treatment market was valued at USD 10,682.6 Mn in 2015, and is expected to reach USD 17,345.8 Mn by 2022, expanding at a CAGR of 7.6% from 2016 to 2022.

Market Insights:

Breast cancer is typically detected either during a screening examination, before symptoms have developed, or after a woman notices a lump. According to market experts, breast cancer is the second-largest cause of cancer deaths globally. The rising prevalence of breast cancer across the developed nations has boosted the involvement of non-governmental associations that are spreading awareness related to breast cancer diagnostics and treatment in public. Therapeutic treatment preferred to treat breast cancer involves synthetic to biological drugs.

Browse the full report Breast Cancer Treatment Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 at

The awareness created around the world in last decade has assisted the market growth along with market introduction of premium priced therapies. Moreover, drugs for breast cancer have seen accelerated approvals, thereby providing impetus for breast cancer research and shifting the equilibrium toward research of new effective pathways for intervention of breast cancer. On the other hand, the geographical analysis of breast cancer treatment market projected North America and Europe as the dominant regions followed by Asia-Pacific.  The key factors driving the breast cancer market in the world include developed research and development facilities, upcoming drug launches, and mounting incidences and awareness of the breast cancer in developing countries. Thus, rising incidences of breast cancer and novel product approvals will lead to significant market growth during the forecast period, despite generic sales erosion resulting from patent expirations.

Pipeline Analysis:

The phase III drugs included in the pipeline analysis are Abemaciclib (Eli Lily & Company), Buparlisib (Novartis), NeuVax (Galena Biopharma), Niraparib (Tesaro), Lynparza (AstraZeneca), Veliparib (AbbVie), Neratinib (Puma Biotechnology), Ribociclib (Novartis) and others. According to market experts, these upcoming drugs assure to provide enhanced efficacy, shorter onset of action and fewer side effects as compared to the currently available breast cancer treatment. Thus, future commercialization of these molecules during the forecast period 2016 – 2022 is anticipated to have a reflective impact on the growth of the overall breast cancer treatment market.

Key Market Movements:

  • North America presently dominates the overall market and is also projected to experience the fastest growth throughout the forecast period
  • The recent market entry of novel drugs including Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent have boosted the overall growth of breast cancer treatment market
  • The companies have been able to develop efficient and commercially successful products by studying pathophysiology of breast cancer in detail, e.g. Herceptin, which is build on the existing scientific groundwork.

Get Sample with more graphs and details for better understanding:


Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Global Breast Cancer Treatment Market Portaiture
2.2 Global Breast Cancer Treatment Market Treament Market, by Drug Class, 2015 (USD Mn)
2.3 Relativity Analysis: Global Breast Cancer Treatment Market, by Geography, 2015 & 2022 (USD Mn)

Chapter 3 Breast Cancer Treatment : Market Dynamics and Outlook
3.1 Breast Cancer Treatment Market Overview
3.2 Breast Cancer Disease Overview and Treatments 
3.2 Market Inclination Insights 
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Breast Cancer Treatment Market, 2015 (Value %)

Chapter 4 Global Breast Cancer Treatment Market, By Type of Drug Class 
4.1 Preface
4.2 HER2 Inhibitors
4.2.1 Trastuzumab
4.2.2 Pertuzumab
4.2.3 Ado-trastuzumab emtansine
4.2.4 Lapatinib
4.3 Mitotic Inhibitors
4.3.1 Eribulin
4.3.2 Docetaxel
4.3.3 Ixabepilone
4.4 Anti-metabolites
4.4.1 Gemcitabine
4.5 Aromatase Inhibitors
4.5.1 Leterozole
4.5.2 Exemestane
4.5.3 Anastrozole
4.5.4 Palbociclib
4.5.5 Everolimus
4.6 Hormone Receptor Antagonists
4.6.1 Goserelin Acetate
4.6.2 Fulvestrant
4.6.3 Toremifene
4.7 Pipeline Analysis
4.7.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn) Abemaciclib Buparlisib NeuVax Niraparib Lynparza Veliparib Neratinib Ribociclib Others
4.7.2 Tabular Representation of Phase II and I Drugs

Chapter 5 Global Breast Cancer Treatment Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia-Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Latin America
5.4.1 Brazil
5.4.2 Mexico
5.4.3 Rest of Latin America
5.6 Middle East and Africa

……….toc continued

Browse the full report Breast Cancer Treatment Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 at

Get Sample with more graphs and details for better understanding:

About Us: 

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Who we are

Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals. Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa. Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.




” What Are the Types of Breast Cancer Treatment?
Some treatments remove or destroy the disease within the breast and nearby tissues, such as lymph nodes. These include:

Surgery to remove the whole breast, called a mastectomy, or to remove just the tumor and tissues around it, called a lumpectomy or breast-conserving surgery. There are different types of mastectomies and lumpectomies.
Radiation therapy, which uses high-energy waves to kill cancer cells.

Other treatments destroy or control cancer cells all over the body:

Chemotherapy uses drugs to kill cancer cells. As these powerful medicines fight the disease, they also can cause side effects, like nausea, hair loss, early menopause, hot flashes, and fatigue.
Hormone therapy uses drugs to prevent hormones, especially estrogen, from fueling the growth of breast cancer cells. Medicines include tamoxifen (Nolvadex, Soltamox) for women before and after menopause and aromatase inhibitors including anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara) for postmenopausal women. Side effects can include hot flashes and vaginal dryness. Some types of this therapy work by stopping the ovaries from making hormones, either through surgery or medication. Fulvestrant (Faslodex) is an injection that keeps estrogen from attaching to cancer cells.
Targeted therapy such as lapatinib (Tykerb), pertuzumab (Perjeta), and trastuzumab (Herceptin). These medicines prompt the body’s immune system to destroy cancer. They target breast cancer cells that have high levels of a protein called HER2. Palbociclib (Ibrance) and ribociclib (Kisqali) work by blocking a substance that promotes cancer growth. Along with an aromatase inhibitor, palbociclib and ribociclib are for postmenopausal women with certain types of advanced cancer. Abemaciclib and palbociclib are sometimes used with the hormone therapy fulvestrant – webmd.

Media Contact
Company Name: Credence Research, Inc
Contact Person: Chris Smith, Global Sales Manager
Email: Send Email
Phone: +1-800-361-8290
Address:105 N 1st ST #429, SAN JOSE, CA 95103 US
State: California
Country: United States